Longwall Ventures

OrganOx Limited, founded in 2008 and based in Oxford, United Kingdom, specializes in organ preservation and transplantation technology, particularly for liver transplants. The company has developed the Metra device, which employs normothermic preservation technology to store livers outside the body at normal body temperature. This innovative approach mimics the conditions of the human body by continuously perfusing the liver with oxygen-carrying red cells and nutrients, thereby preventing the decay of the organ before transplantation. The Metra device enables the liver to produce bile, metabolize glucose, and maintain a physiological pH level, ultimately enhancing the viability of the organ for transplant. OrganOx's research and development efforts are rooted in the work of Prof Peter Friend and Prof Constantin Coussios at the University of Oxford.

Biofidelity Ltd. is a company focused on the research and development of molecular diagnostic assays designed for the detection of specific DNA sequences. Founded in 2019 and based in Cambridge, United Kingdom, Biofidelity's innovative assays have applications in various fields, including oncology, prenatal testing, infectious disease, and organ transplant monitoring. The company's mission is to enhance patient care by facilitating early disease detection and improving the targeting of treatments, ultimately aiming to improve and extend patients' lives.

Wayland Additive is a company based in Huddersfield, United Kingdom, specializing in the development, manufacture, and distribution of metal additive manufacturing 3D printing machines. Founded in 2019, the company focuses on advancing electron beam 3D printing technology, aiming to serve industrial end-users in sectors such as aerospace and medical. Wayland Additive’s machines are designed to provide superior process monitoring, control, and versatility, enabling the use of high-performance materials that are challenging to work with. This innovation allows clients to achieve high precision and complexity in their manufacturing processes, thereby enhancing product performance across various industries, including energy and tooling.

Lightcast Discovery Limited, founded in 2019 and based in Cambridge, United Kingdom, specializes in advancing drug discovery through its innovative microfluidic platform. This technology allows for precise control of thousands of droplets, enabling complex cell analysis and workflows without manual manipulation. By leveraging this platform, Lightcast collaborates with major pharmaceutical companies and leading academic institutions to develop new therapies and products. The company's focus is on pushing the boundaries of complex cell analysis, thereby facilitating the discovery of unique clinical approaches in the field of drug development.

Wayland Additive is a company based in Huddersfield, United Kingdom, specializing in the development, manufacture, and distribution of metal additive manufacturing 3D printing machines. Founded in 2019, the company focuses on advancing electron beam 3D printing technology, aiming to serve industrial end-users in sectors such as aerospace and medical. Wayland Additive’s machines are designed to provide superior process monitoring, control, and versatility, enabling the use of high-performance materials that are challenging to work with. This innovation allows clients to achieve high precision and complexity in their manufacturing processes, thereby enhancing product performance across various industries, including energy and tooling.

Caristo Diagnostics Limited, founded in 2018 as a spin-out from the University of Oxford, specializes in artificial intelligence-based software for diagnosing cardiovascular conditions. The company has developed the CaRi-Heart technology, an advanced imaging platform that enhances the prediction and diagnosis of coronary artery disease, heart attacks, strokes, and diabetes. Utilizing Cardiac Computed Tomography Angiography (CCTA), the platform measures the Fat Attenuation Index (FAI), a patented biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical insights, including patient-specific FAI, an assessment of the absolute 8-year risk of a fatal heart attack, and detailed characterization of coronary plaque. The technology is CE Mark certified and has received recognition in prestigious medical journals, showcasing its efficacy in predicting heart attacks. Caristo has secured over £23 million in venture capital and has been supported by various UK government grants for its innovative care pathways. With its unique combination of clinical insights and advanced technology, Caristo aims to transform cardiac care globally by improving risk prediction and prevention strategies.

MicrofluidX Ltd is a company focused on advancing cell bioprocessing for autologous cell and gene therapy manufacturing. Founded in 2018 and headquartered in London, United Kingdom, the company has developed an innovative microfluidic bioprocessing system that integrates various cell culture functions, including seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting within a single, automated, closed system. This technology addresses challenges related to process control, scalability, and cost in cell bioprocessing, enabling biologists to efficiently conduct process development by exploring numerous cell culture conditions.

MIRICO Ltd. is a laser spectroscopy instrumentation company based in Oxford, United Kingdom, founded in December 2015. The company specializes in developing high-performance gas sensing technology using Laser Dispersion Spectroscopy. MIRICO's innovative instruments are designed for trace gas analysis and provide precise, real-time measurements of gas emissions, even in challenging weather conditions. Its offerings include stable isotope analyzers for space exploration and advanced monitoring solutions for applications in environmental monitoring, geochemistry, medical diagnosis, and oil and gas exploration. Through autonomous and continuous monitoring capabilities, MIRICO enables industries to track emissions effectively and gain insights into their operations, contributing to efforts aimed at achieving net-zero emissions and enhancing productivity. The company emerged as a spin-out from the Laser Spectroscopy Group at the STFC Rutherford Appleton Laboratory and is located on the Harwell Science & Innovation Campus.

Helio Display Materials specializes in developing innovative perovskite-based materials designed to enhance the performance and efficiency of display technologies. By utilizing metal halide perovskites, the company creates materials that enable displays to produce richer and more vibrant colors while consuming significantly less power. Helio's mission focuses on improving the overall visual experience, making displays brighter and more colorful. The company is committed to advancing research and development in this field by collaborating with scientific and industry experts, ensuring a strong intellectual property foundation rooted in scientific principles. Through its groundbreaking materials, Helio aims to revolutionize the display industry, particularly for televisions and other visual technologies.

Wayland Additive is a company based in Huddersfield, United Kingdom, specializing in the development, manufacture, and distribution of metal additive manufacturing 3D printing machines. Founded in 2019, the company focuses on advancing electron beam 3D printing technology, aiming to serve industrial end-users in sectors such as aerospace and medical. Wayland Additive’s machines are designed to provide superior process monitoring, control, and versatility, enabling the use of high-performance materials that are challenging to work with. This innovation allows clients to achieve high precision and complexity in their manufacturing processes, thereby enhancing product performance across various industries, including energy and tooling.

Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, focused on developing innovative solutions that combine prescription drugs with digital therapies. Founded by a team of experienced healthcare professionals and life scientists, the company aims to optimize medication dosing through real-time feedback and linked behavioral therapy to enhance patient outcomes. Currently, Closed Loop Medicine is developing products targeting hypertension and insomnia, alongside a diverse pipeline addressing various chronic diseases. The company prioritizes the needs of both patients and clinicians in the design and development of its offerings, striving to integrate technology effectively within the healthcare system.

Iothic is a developer of a decentralized platform that offers point-to-point quantum-resistant authentication and encryption. The company focuses on delivering a secure, scalable, and robust authentication solution that operates across various operating systems, protocols, communication layers, and IoT stacks. This enables network providers to efficiently establish autonomous authentication services for a range of applications, from simple sensors to complex Internet of Things (IoT) systems. By ensuring full peer-to-peer network interoperability, Iothic addresses the growing need for secure and resilient communication in an increasingly interconnected digital landscape.

Caristo Diagnostics Limited, founded in 2018 as a spin-out from the University of Oxford, specializes in artificial intelligence-based software for diagnosing cardiovascular conditions. The company has developed the CaRi-Heart technology, an advanced imaging platform that enhances the prediction and diagnosis of coronary artery disease, heart attacks, strokes, and diabetes. Utilizing Cardiac Computed Tomography Angiography (CCTA), the platform measures the Fat Attenuation Index (FAI), a patented biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical insights, including patient-specific FAI, an assessment of the absolute 8-year risk of a fatal heart attack, and detailed characterization of coronary plaque. The technology is CE Mark certified and has received recognition in prestigious medical journals, showcasing its efficacy in predicting heart attacks. Caristo has secured over £23 million in venture capital and has been supported by various UK government grants for its innovative care pathways. With its unique combination of clinical insights and advanced technology, Caristo aims to transform cardiac care globally by improving risk prediction and prevention strategies.

Kinomica Limited is a medicine research and diagnostics company based in Macclesfield, United Kingdom, focused on enhancing treatment decisions for cancer patients and other conditions. The company has developed KScan, a phosphoproteomic diagnostic platform that measures intracellular kinase activity and cell-signaling pathways in cells and tissues. This platform aims to assist clinicians in prescribing the appropriate drug for individual patients by providing advanced bioinformatics and analytical methods to assess the activity of multiple endogenous kinases. By enabling detailed insights into disease mechanisms and facilitating drug targeting and biomarker identification, Kinomica strives to improve tailored treatment strategies in anticancer therapies. Kinomica was previously known as Pronostics Ltd. before adopting its current name in May 2017.

MicrofluidX Ltd is a company focused on advancing cell bioprocessing for autologous cell and gene therapy manufacturing. Founded in 2018 and headquartered in London, United Kingdom, the company has developed an innovative microfluidic bioprocessing system that integrates various cell culture functions, including seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting within a single, automated, closed system. This technology addresses challenges related to process control, scalability, and cost in cell bioprocessing, enabling biologists to efficiently conduct process development by exploring numerous cell culture conditions.

LettUs Grow is a company based in Bristol, United Kingdom, that specializes in aeroponic irrigation and control technology aimed at enhancing the efficiency and sustainability of indoor farming. Founded in 2015, the company develops modular aeroponic systems that allow plants to grow without soil, using a fine mist for watering and LED lighting to facilitate photosynthesis. Their technology is designed to be nozzle-free and easy to clean, promoting automation and minimizing the need for pesticides. Additionally, LettUs Grow offers farm management software and data services that optimize agricultural practices, helping to reduce labor costs and improve growing conditions for various plant species. By focusing on innovation in farming, LettUs Grow aims to lower the environmental impact of agriculture and support sustainable business practices in the industry.

Wayland Additive is a company based in Huddersfield, United Kingdom, specializing in the development, manufacture, and distribution of metal additive manufacturing 3D printing machines. Founded in 2019, the company focuses on advancing electron beam 3D printing technology, aiming to serve industrial end-users in sectors such as aerospace and medical. Wayland Additive’s machines are designed to provide superior process monitoring, control, and versatility, enabling the use of high-performance materials that are challenging to work with. This innovation allows clients to achieve high precision and complexity in their manufacturing processes, thereby enhancing product performance across various industries, including energy and tooling.

Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, focused on developing innovative solutions that combine prescription drugs with digital therapies. Founded by a team of experienced healthcare professionals and life scientists, the company aims to optimize medication dosing through real-time feedback and linked behavioral therapy to enhance patient outcomes. Currently, Closed Loop Medicine is developing products targeting hypertension and insomnia, alongside a diverse pipeline addressing various chronic diseases. The company prioritizes the needs of both patients and clinicians in the design and development of its offerings, striving to integrate technology effectively within the healthcare system.

Verdel Instruments Ltd specializes in the development of two-dimensional mass spectrometry (2DMS) equipment designed for structural analysis and sequencing. Established in 2018 and headquartered in Coventry, United Kingdom, the company offers advanced mass spectrometry technology that facilitates the identification of key components and impurities in various sectors, including biopharmaceuticals, food, chemicals, and environmental analysis. This innovative technology allows researchers to obtain comprehensive structural information from complex mixtures by enabling the fragmentation of multiple molecules while maintaining a correlation between each fragment and its precursor. Verdel Instruments' solutions deliver detailed fragmentation datasets rapidly, enhancing the efficiency and effectiveness of analytical processes in laboratories.

Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, focused on developing innovative solutions that combine prescription drugs with digital therapies. Founded by a team of experienced healthcare professionals and life scientists, the company aims to optimize medication dosing through real-time feedback and linked behavioral therapy to enhance patient outcomes. Currently, Closed Loop Medicine is developing products targeting hypertension and insomnia, alongside a diverse pipeline addressing various chronic diseases. The company prioritizes the needs of both patients and clinicians in the design and development of its offerings, striving to integrate technology effectively within the healthcare system.

Caristo Diagnostics Limited, founded in 2018 as a spin-out from the University of Oxford, specializes in artificial intelligence-based software for diagnosing cardiovascular conditions. The company has developed the CaRi-Heart technology, an advanced imaging platform that enhances the prediction and diagnosis of coronary artery disease, heart attacks, strokes, and diabetes. Utilizing Cardiac Computed Tomography Angiography (CCTA), the platform measures the Fat Attenuation Index (FAI), a patented biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical insights, including patient-specific FAI, an assessment of the absolute 8-year risk of a fatal heart attack, and detailed characterization of coronary plaque. The technology is CE Mark certified and has received recognition in prestigious medical journals, showcasing its efficacy in predicting heart attacks. Caristo has secured over £23 million in venture capital and has been supported by various UK government grants for its innovative care pathways. With its unique combination of clinical insights and advanced technology, Caristo aims to transform cardiac care globally by improving risk prediction and prevention strategies.

Oxford Space Systems Limited, founded in 2013 and based in Harwell, United Kingdom, specializes in the development, manufacture, and marketing of deployable hardware structures for space environments. The company focuses on creating innovative deployable antennas, panels, hinge systems, and composite linear boom systems, utilizing advanced design techniques such as origami and proprietary materials. These technologies aim to produce structures that are lighter, less complex, and more cost-effective than traditional alternatives, catering to the global satellite industry. Oxford Space Systems has gained recognition for its rapid product development, notably with its AstroTube Boom, which achieved successful deployment in under 30 months. The company has engaged in various co-development projects supported by the UK government, collaborating with leading European satellite manufacturers and securing commercial contracts in Asia and the US. With a growing team of professionals possessing extensive experience in the space sector, Oxford Space Systems operates from a custom facility at the Harwell Space Cluster, equipped to handle defense and security contracts.

MIRICO Ltd. is a laser spectroscopy instrumentation company based in Oxford, United Kingdom, founded in December 2015. The company specializes in developing high-performance gas sensing technology using Laser Dispersion Spectroscopy. MIRICO's innovative instruments are designed for trace gas analysis and provide precise, real-time measurements of gas emissions, even in challenging weather conditions. Its offerings include stable isotope analyzers for space exploration and advanced monitoring solutions for applications in environmental monitoring, geochemistry, medical diagnosis, and oil and gas exploration. Through autonomous and continuous monitoring capabilities, MIRICO enables industries to track emissions effectively and gain insights into their operations, contributing to efforts aimed at achieving net-zero emissions and enhancing productivity. The company emerged as a spin-out from the Laser Spectroscopy Group at the STFC Rutherford Appleton Laboratory and is located on the Harwell Science & Innovation Campus.

Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, focused on developing innovative solutions that combine prescription drugs with digital therapies. Founded by a team of experienced healthcare professionals and life scientists, the company aims to optimize medication dosing through real-time feedback and linked behavioral therapy to enhance patient outcomes. Currently, Closed Loop Medicine is developing products targeting hypertension and insomnia, alongside a diverse pipeline addressing various chronic diseases. The company prioritizes the needs of both patients and clinicians in the design and development of its offerings, striving to integrate technology effectively within the healthcare system.

Base4 specializes in the innovation and development of advanced technologies for single-molecule analysis, specifically focusing on microdroplet-based sequencing. This technology facilitates pathogen screening and DNA analysis by generating long reads from individual DNA molecules without requiring initial amplification. As a result, Base4's solutions enable users to better understand and predict diseases while providing cost-effective and accurate sequencing data for large populations. The company is committed to building a valuable portfolio of intellectual property and technical expertise that underpins its innovative offerings.

Arquer Diagnostics Ltd. specializes in the design, development, and commercialization of non-invasive diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring specific substances in bodily fluids, including a CE-marked ELISA kit for Mcm5, which is utilized in hospital laboratories. Additionally, Arquer provides a point-of-care system that features a robust reader instrument and disposable cartridges, making it suitable for urology clinics, hospital laboratories, and general practitioners' surgeries. Founded in 2005 and based in Sunderland, United Kingdom, the company was previously known as UroSens Ltd. before rebranding in July 2015. Arquer’s patented technology allows for accurate and reliable detection of the MCM5 protein, aiding in cancer diagnosis and monitoring.

OxSonics Therapeutics is a biotechnology company focused on improving anti-cancer therapies through its innovative SonoTran platform. This technology enhances the delivery of anti-cancer agents to solid tumors by disrupting their structure, thereby increasing efficacy and reducing toxicity without the need for drug reformulation. SonoTran operates by co-administering particles with anti-cancer drugs, creating a localized pumping effect that improves drug penetration within tumors. Designed to integrate seamlessly into existing oncology workflows, the platform also allows healthcare professionals to visualize treatment progress in real-time. Originating from research at the University of Oxford’s Institute of Biomedical Engineering, OxSonics is headquartered in Oxford, UK.

Keit Ltd. specializes in the design and manufacture of advanced spectrometers and related instruments that operate across a spectrum from ultraviolet to far infrared rays. Established in 2012 and based in Didcot, United Kingdom, the company focuses on innovative applications for its products, which include the measurement of signal levels, vibrations, and various substances in both gas and liquid forms. One of Keit's flagship products is the microFTS®, a compact and rugged Fourier Transform Infrared (FTIR) spectrometer originally developed for space applications. This device sets a new benchmark for real-time liquid-state analyses and serves industries such as pharmaceuticals, chemicals, oil and gas, and food and beverage, where performance in extreme environments is crucial.

MIRICO Ltd. is a laser spectroscopy instrumentation company based in Oxford, United Kingdom, founded in December 2015. The company specializes in developing high-performance gas sensing technology using Laser Dispersion Spectroscopy. MIRICO's innovative instruments are designed for trace gas analysis and provide precise, real-time measurements of gas emissions, even in challenging weather conditions. Its offerings include stable isotope analyzers for space exploration and advanced monitoring solutions for applications in environmental monitoring, geochemistry, medical diagnosis, and oil and gas exploration. Through autonomous and continuous monitoring capabilities, MIRICO enables industries to track emissions effectively and gain insights into their operations, contributing to efforts aimed at achieving net-zero emissions and enhancing productivity. The company emerged as a spin-out from the Laser Spectroscopy Group at the STFC Rutherford Appleton Laboratory and is located on the Harwell Science & Innovation Campus.

User Replay Limited develops digital customer experience analytics software solutions that help businesses enhance their online interactions with customers. Founded in 2009 and based in Reading, United Kingdom, the company provides an integrated customer experience platform that utilizes machine learning to identify and analyze user sessions effectively. Its Active CX platform records and analyzes digital customer interactions, enabling businesses to uncover and address conversion barriers such as usability issues, confusing business logic, and technical problems. User Replay’s software is designed to improve user experience and increase conversion rates, which can have a direct impact on sales. The company serves various sectors, including financial services, insurance, retail, and travel, with operations across Europe, the Middle East, Africa, and the United States. User Replay's solutions are utilized by over 20 leading brands, including notable retailers in the US and Europe.

Oxford Cancer Biomarkers specializes in the development and commercialization of colorectal cancer biomarker tests aimed at enhancing treatment pathways. Associated with the Institute of Cancer Medicine at Oxford University, the company leverages its founders' expertise in translational cancer science. It has formed partnerships with pharmaceutical companies to utilize its discovery platforms, CancerNav® and ToxNav™, in the creation of companion diagnostic tests for emerging therapies. The tests developed by Oxford Cancer Biomarkers assess dihydropyridine dehydrogenase deficiency and related variants, which are linked to partial dihydropyrimidine deficiency and increased toxicity risks. This innovation enables healthcare providers and patients to analyze resected tissue samples to evaluate the likelihood of cancer relapse, thereby advancing personalized medicine in oncology.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

Arquer Diagnostics Ltd. specializes in the design, development, and commercialization of non-invasive diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring specific substances in bodily fluids, including a CE-marked ELISA kit for Mcm5, which is utilized in hospital laboratories. Additionally, Arquer provides a point-of-care system that features a robust reader instrument and disposable cartridges, making it suitable for urology clinics, hospital laboratories, and general practitioners' surgeries. Founded in 2005 and based in Sunderland, United Kingdom, the company was previously known as UroSens Ltd. before rebranding in July 2015. Arquer’s patented technology allows for accurate and reliable detection of the MCM5 protein, aiding in cancer diagnosis and monitoring.

Sensiia Limited is a company based in Cambridge, United Kingdom, that specializes in the manufacturing of sensor-based fertility wearable devices, notably the DuoFertility system. Founded in 2006 and formerly known as Cambridge Temperature Concepts Limited, Sensiia develops a comprehensive fertility solution that includes a wearable device and a supporting mobile application. DuoFertility tracks and predicts female ovulation cycles, providing users with insights into their most fertile windows up to 10 days in advance. This system is unique in offering personalized support from fertility experts, enhancing the user experience in their journey toward pregnancy. Clinically proven to be as effective as the first cycle of IVF, DuoFertility has demonstrated significant success rates in helping couples conceive, with results comparable to traditional fertility treatments. Sensiia's innovative approach addresses a critical need in reproductive health, aiming to improve outcomes for individuals seeking to expand their families.

Momentum Bioscience Ltd is a biotechnology company specializing in the development of rapid diagnostic tests for critical clinical specimens. Established in 2005 and based in Cardiff, United Kingdom, the company utilizes its innovative Enzyme Mediated Amplification (EMA) technology to enable the universal detection of viable bacteria and fungi in under two hours, significantly reducing the time compared to traditional laboratory methods that can take 1 to 5 days. Momentum Bioscience's products are particularly valuable in neonatal care, emergency care, and critical care settings, as they specifically measure viable organisms, ensuring accurate detection of infections in blood and other normally sterile body fluids. The company is focused on advancing its suite of related technologies to enhance pathogen detection and support microbiology laboratories.

Oxford Space Systems Limited, founded in 2013 and based in Harwell, United Kingdom, specializes in the development, manufacture, and marketing of deployable hardware structures for space environments. The company focuses on creating innovative deployable antennas, panels, hinge systems, and composite linear boom systems, utilizing advanced design techniques such as origami and proprietary materials. These technologies aim to produce structures that are lighter, less complex, and more cost-effective than traditional alternatives, catering to the global satellite industry. Oxford Space Systems has gained recognition for its rapid product development, notably with its AstroTube Boom, which achieved successful deployment in under 30 months. The company has engaged in various co-development projects supported by the UK government, collaborating with leading European satellite manufacturers and securing commercial contracts in Asia and the US. With a growing team of professionals possessing extensive experience in the space sector, Oxford Space Systems operates from a custom facility at the Harwell Space Cluster, equipped to handle defense and security contracts.

Oxford PV is a company based in Oxford, United Kingdom, that specializes in the development and commercialization of thin-film perovskite solar cells. Founded in 2010 by Henry Snaith and Kevin Arthur, the company focuses on integrating these solar cells with traditional silicon solar cells, CIGS solar cells, or glass. Oxford PV's innovative technology enhances photovoltaic performance by effectively capturing specific parts of the solar spectrum, providing a low-cost, thin-film alternative for renewable energy generation. The company's mission supports the global transition to sustainable energy solutions.

OrganOx Limited, founded in 2008 and based in Oxford, United Kingdom, specializes in organ preservation and transplantation technology, particularly for liver transplants. The company has developed the Metra device, which employs normothermic preservation technology to store livers outside the body at normal body temperature. This innovative approach mimics the conditions of the human body by continuously perfusing the liver with oxygen-carrying red cells and nutrients, thereby preventing the decay of the organ before transplantation. The Metra device enables the liver to produce bile, metabolize glucose, and maintain a physiological pH level, ultimately enhancing the viability of the organ for transplant. OrganOx's research and development efforts are rooted in the work of Prof Peter Friend and Prof Constantin Coussios at the University of Oxford.

Crysalin Limited, founded in June 2007 in London, focuses on the research and development of crysalin lattice technology, which originated from patented work at Oxford University. The company specializes in crysalins, a protein-based nanotechnology that significantly enhances protein structure determination, particularly for challenging macromolecular targets such as membrane proteins and flexible soluble proteins. By imposing order on these targets, crysalins enable advanced imaging techniques like X-ray crystallography and electron microscopy to resolve three-dimensional molecular structures that other methods cannot. In addition to protein structure determination, Crysalin's technology holds promise for applications in biosensor development and optoelectronics, positioning the company as a key player in the field of biophysical research and nanotechnology.

Diamond Microwave Devices Ltd. specializes in the development of semiconductor devices utilizing chemical vapor deposition (CVD) diamond technology. Founded in 2006 and headquartered in Leeds, United Kingdom, the company focuses on creating devices that serve both civil and defense sectors, specifically for microwave power amplifier and transmitter applications. As a subsidiary of Element Six (Pty) Ltd., Diamond Microwave Devices aims to advance the performance and efficiency of microwave technologies through innovative diamond-based solutions.